French Biotech scene has been growing up to the point to reach countries such as the United States and United Kingdom. France nowadays is one of the Europe’s most established hubs for biotech research. The close collaboration between renown foundations, companies, and public institutions such as Institute Curie, CNRS, AB science, and others with the French government have placed France as leader of the biotech industry in Europe. 

The healthcare sector in Canada is broad and full of opportunities for business and trade. It is delivered through the territorial systems of Publicity funded Health Care or just “Medicare”, even when it is considered a single-payer system where public entities control most of the sector, the industry is moving towards a close relationship with tech ventures as well as manufacturers. The COVID pandemic showed that Canada’s health was overreliant on overseas manufacturing. Having spent part of the pandemic competing for ventilators and vaccines in the global markets, the government now pushes hard to bring the production of health devices and technology back to the country.

The U.S. healthcare system is considered as the most controversial one. Even though that the healthcare services are considered of the highest quality, there is a considerable amount of the population that is excluded from healthcare provision. There has been some efforts to make the sector more inclusive but still there is a long way to go. The opportunies that the industry offers in numerous sectors of the industry, such as insurance, pharmaceuticals, and medical devices are limitless. The U.S. healthcare industry is very interesting to explore.

Health care in the United Kingdom is divided into four different systems, one for every nation, and their parliaments and governments fund it. The average healthcare expenditure in the UK amounted to 10.2% of the GDP, the institutions are mainly public, and the “National Health Service” from England is the central entity. But A dominant public healthcare does not mean there is no space for privates organization or innovations.